Hydroxamic Acid Based Histone Deacetylase Inhibitors: Present and Future Prospectives as Anticancer Agent

[1]  B. Venugopal,et al.  Developing histone deacetylase inhibitors as anti-cancer therapeutics. , 2011, Current medicinal chemistry.

[2]  A. Zambrano,et al.  Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[3]  P. Marks,et al.  Histone Deacetylase Inhibitors: Overview and Perspectives , 2007, Molecular Cancer Research.

[4]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[5]  R. Marmorstein,et al.  Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design , 2007, Oncogene.

[6]  A. Mai.  The therapeutic uses of chromatin-modifying agents , 2007, Expert opinion on therapeutic targets.

[7]  Michele Pallaoro,et al.  HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics , 2007, Cell Research.

[8]  Brian K. Kennedy,et al.  Sirtuins in Aging and Age-Related Disease , 2006, Cell.

[9]  L. Schwartz,et al.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Bhalla.  Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Mai,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[12]  A. Ho,et al.  Role of histone deacetylase inhibitors in the treatment of cancer (Review). , 2004, International journal of oncology.

[13]  P. M. Das,et al.  DNA methylation and cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[15]  S. Grant,et al.  Histone deacetylase inhibitors in clinical development , 2004, Expert opinion on investigational drugs.

[16]  K. Glaser,et al.  A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. , 2003, Bioorganic & medicinal chemistry letters.

[17]  S. Kyrylenko,et al.  Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases , 2003, Cellular and Molecular Life Sciences CMLS.

[18]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[19]  T. Ekström,et al.  The human histone deacetylase family. , 2001, Experimental cell research.

[20]  P. Marks,et al.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.

[21]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[22]  Y. Agrawal.  Hydroxamic Acids and Their Metal Complexes , 1979 .

[23]  K. F. Fouché,et al.  Complex formation of Zr(IV) and Hf(IV) with hydroxamic acids in acidic solutions , 1970 .

[24]  G. Grossi,et al.  The complexing power of hydroxamic acids and its effect on behaviour of organic extractants in the reprocessing of irradiated fuels—II: The complexes between benzohydroxamic acid and thorium, uranium (IV) and plutonium (IV) , 1966 .

[25]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[26]  James M. Morrell,et al.  Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. , 2007, Bioorganic & medicinal chemistry letters.

[27]  Chunlei Zhang,et al.  Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). , 2007, Blood.

[28]  L. Schwartz,et al.  Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. , 2006, Clinical lung cancer.

[29]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[30]  W. Kelly.  Histone deacetylase inhibitors. , 2004, Clinical advances in hematology & oncology : H&O.

[31]  K. Nagashima,et al.  A new antifungal antibiotic, trichostatin. , 1976, The Journal of antibiotics.